Getinge completed the acquisition of Applikon Biotechnology for $89m.

Getinge, a medical technology company, completed the acquisition of Applikon Biotechnology, a manufacturer and supplier of bioreactor systems for $89m. Applikon Biotechnology is expected to bring a material contribution to Getinge’s Life Science business area in terms of net sales and EBITA. The acquisition broadens Getinge’s position further within solutions for efficient, safe and contamination-free research and production processes in the biopharma segment. "Through Applikon Biotechnology, Getinge will be able to offer customers better solutions and knowledge covering the entire process from initial screening to full-scale production, using a fully scalable platform," Arthur Oudshoorn, Applikon Biotechnology CEO.